RESEARCH PEPTIDE FUNDAMENTALS / QUESTIONS
Questions this desk gets asked
Short answers, cited where a number is involved, and an honest refusal where the literature has nothing to offer.
What does BPC-157 do in the body?
In animals it accelerates tissue repair, and the most consistent explanation is angiogenesis — the growth of new blood vessels. Work across chick membrane, rat hindlimb-ischaemia and human endothelial-cell models found that it raises VEGFR2 expression and promotes the receptor's internalisation, activating the VEGFR2–Akt–eNOS pathway, with increased vessel density and faster blood-flow recovery in ischaemic muscle [4]. Other reported routes include the FAK–paxillin migration complex and sensitisation of the growth hormone receptor in tendon fibroblasts. In humans, essentially none of this has been measured: only three small pilot studies exist [2].
Is BPC-157 a growth hormone?
No. It is a fifteen-amino-acid peptide derived from a protein in gastric juice, and it is not structurally or functionally a growth hormone. The confusion has a real root: in cultured tendon cells BPC-157 increased growth-hormone-receptor signalling, which is one proposed part of how it influences repair. Making a tissue more responsive to a hormone is not the same as being that hormone. Ipamorelin, by contrast, does act on the growth hormone axis, by triggering release of the hormone from the pituitary [11] — which is exactly why the two compounds belong on separate pages.
Does BPC-157 work immediately?
There is no human efficacy trial to answer this, so no timeline can be quoted from the literature. What is documented is that the molecule clears quickly: in rats and beagle dogs the elimination half-life was under thirty minutes, with rapid breakdown into small fragments entering ordinary amino-acid metabolism [3]. Fast clearance argues against any effect that depends on the compound persisting in circulation. Community reports describe improvements over one to three weeks, but those are anecdotal, not clinical evidence, and they describe preparations whose content was never verified.
Does BPC-157 damage the liver?
No published human study shows liver damage, and no published human study is large enough to rule it out. The only relevant human data point is a first-in-human intravenous safety pilot in which BPC-157 up to 20 mg was given to two healthy adults with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two participants cannot establish organ safety. The honest answer is that hepatic safety in humans is uncharacterised, which a 2025 review makes clear when it counts only three human pilot studies in the entire literature [2].
What is ipamorelin?
A synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that selectively activates the ghrelin receptor GHS-R1a on pituitary cells and triggers a pulse of growth hormone. Its founding characterisation established it as the first highly growth-hormone-selective secretagogue: potent release in rat pituitary cells, anaesthetised rats and conscious swine — a swine half-maximal effective dose of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 — without raising ACTH or cortisol above the level seen with growth-hormone-releasing hormone, even at more than 200 times the growth-hormone half-maximal dose [11]. It has never been approved as a medicine anywhere.
What does ipamorelin do for the people who use it?
Two answers, and the gap between them is the point. In the published record, the only controlled human trial gave 114 adults recovering from bowel resection 0.03 mg/kg intravenously twice daily for up to seven days, and it missed its primary endpoint: median time to a first tolerated meal was 25.3 hours against 32.6 hours on placebo, p=0.15 [8]. In research-use communities the most frequently reported experiences are deeper sleep, vivid dreams early on, and faster recovery from training — anecdotal, not clinical evidence, attached to preparations of unverified content, and describing outcomes no ipamorelin trial has ever measured.
What are the risks of ipamorelin?
The documented risks are mostly risks of not knowing. There is no Phase 3 trial and no long-term human safety database; the entire controlled human record is one short perioperative trial [8] and one acute pharmacokinetic study [9]. Beyond that, three mechanism-based concerns recur: growth hormone raises IGF-1, a well-characterised mitogen, which creates a theoretical concern in existing or occult malignancy [10] [11]; growth hormone reduces insulin sensitivity while the compound also acts directly on pancreatic islet cells in preclinical work, making the net glycaemic effect unpredictable [11]; and a 28-day study of a different agonist at the same receptor found dose-dependent myocardial degeneration in rats, with ipamorelin itself untested over comparable durations [7].
What is tirzepatide?
A thirty-nine-amino-acid synthetic peptide that activates both the GIP and the GLP-1 receptor, making it the first approved dual incretin agonist. A fatty-diacid arm binds albumin and extends its duration of action enough for once-weekly administration in trials. The FDA approved it in May 2022 for type 2 diabetes [14], and subsequently for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity. Approved formulations are prescription-only. It is the only compound covered on this site that is an approved medicine.
How does tirzepatide work?
By imitating two gut hormones at once. Engaging both the GIP and GLP-1 receptors enhances insulin secretion in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake [14]. Because insulin release is glucose-dependent, the intrinsic risk of driving blood sugar too low is modest, though it rises when the agent is combined with insulin or a sulfonylurea. Head-to-head trials support the claim that engaging two receptors does more than one: -20.2 per cent against -13.7 per cent body weight over 72 weeks versus semaglutide [13].
What is tirzepatide used for?
Its approved indications are type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnoea in adults with obesity [14]. The trial evidence behind those uses is substantial: mean weight change of -20.9 per cent at the 15 mg dose over 72 weeks against -3.1 per cent on placebo in 2,539 adults [16], and glycated haemoglobin reductions of up to 2.30 percentage points against 1.86 for semaglutide 1 mg in 1,879 adults with type 2 diabetes [17]. Prescribing decisions belong to a clinician; this page reports the record, nothing more.
Does a research-use-only designation mean the material has been checked for purity?
No. That designation describes permitted use, not content. It is not a purity grade, not a certification, and it carries no assay obligation a reader could inspect. Two preparations carrying the same designation can differ completely in what they contain, and the wording itself gives no way to distinguish them. The point is easiest to see with tirzepatide: the approved product carries an inspected manufacturing system and a filed evidence package, while the same chemical name on unverified material carries neither, and regulators said as much about compounded material during a documented shortage period.
Can the published literature identify what is in an unverified vial?
It cannot, and that is worth stating without hedging. Every study in this site's reference list used material that was characterised before the experiment began — that is a precondition of publishing a result at all. No paper here examined a preparation obtained outside a controlled research setting, and none claims to. So the literature offers no register of contents, no sampling programme and no basis for any figure about how often such material matches its label. The consequence is the argument this whole site is built on: an effect attributed to a preparation of unknown content is uninterpretable, because the molecule, the rest of the vial, and the passage of time cannot be told apart.